PMI (NYSEAMERICAN:PMI) Rating Increased to Hold at Zacks Research

PMI (NYSEAMERICAN:PMI) was upgraded by analysts at Zacks Research to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

Separately, HC Wainwright initiated coverage on shares of PMI in a report on Monday. They issued a “neutral” rating for the company. Two equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company has an average rating of “Hold”.

PMI Stock Down 3.7%

Shares of PMI stock opened at $0.15 on Tuesday. PMI has a 12-month low of $0.13 and a 12-month high of $13.68. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.75 and a quick ratio of 0.72. The firm has a 50-day moving average of $0.78.

PMI (NYSEAMERICAN:PMI) last issued its earnings results on Friday, May 15th. The company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of $1.15 million for the quarter. As a group, equities research analysts forecast that PMI will post -0.17 earnings per share for the current year.

More PMI News

Here are the key news stories impacting PMI this week:

• Neutral Sentiment: HC Wainwright reiterated a Neutral stance on PMI while publishing updated estimates across 2026 and 2027, including projected losses in every period and full-year EPS of ($0.17) for FY2026 and ($0.09) for FY2027. PMI analyst coverage
• Neutral Sentiment: The most recent quarterly results also showed PMI remained unprofitable, with the company posting ($0.10) EPS on $1.15 million in revenue, reinforcing concerns about near-term profitability. PMI earnings results
• Negative Sentiment: Multiple analyst forecasts for the next several quarters point to continued losses, which can weigh on investor sentiment and keep pressure on the stock. PMI earnings estimates

About PMI

Picard Medical Inc is a medical technology company which manufactures and sells the only total artificial heart. Picard Medical Inc is based in TUCSON, Ariz.